← Evidence map

ArticleBiomedicines2026

Adropin, S100A1, and SERCA2b Dysregulation in Coronary Artery Disease: Molecular and In Silico Insights into Calcium Signaling and Metabolic Dysfunction.

Onur Aslan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Adropin, S100A1, and SERCA2b Dysregulation in Coronary Artery Disease: Molecular and In Silico Insights into Calcium Signaling and Metabolic Dysfunction. | OpenQuestion